Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of this study was to assess the relationship between polymorphisms involving five cytokine genes (TNF-alpha, TGF-beta, IL-10, IL-6, and IFN-gamma), and IBD susceptibility and disease phenotype.
|
15842590 |
2005 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of the study was to evaluate bone mineral density (BMD) by densitometry and the concentration of interleukin 6, osteoprotegerin (OPG) and sRANKL protein (sRANKL) by ELISA in patients with IBD in relation to the control group; to assess the relationship between IL-6, OPG, sRANKL and BMD; and to assess the impact of disease duration and number hospitalization on BMD.
|
29558031 |
2018 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Evidence of active cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases.
|
12792220 |
2003 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
We used recombinant sgp130Fc protein and recently generated transgenic mice expressing high levels of sgp130Fc to discriminate between classic and trans-signaling in vivo, and demonstrated that IL-6 trans-signaling is critically involved in generation and maintenance of several inflammatory and autoimmune diseases including chronic inflammatory bowel disease, rheumatoid arthritis, peritonitis and asthma, as well as inflammation-induced colon cancer.
|
21145125 |
2011 |
Inflammatory Bowel Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, more recent evidence from various autoimmune diseases (e.g., inflammatory bowel disease, rheumatoid arthritis) has shown that the IL-6 activity is more complex with important effects also on tissue homeostasis, regeneration, and metabolism.
|
28642760 |
2017 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The interleukin-6 (IL-6)/STAT3 signaling regulates survival and proliferation of intestinal epithelial cells and plays an important role in the pathogenesis of inflammatory bowel disease and colorectal cancer.
|
24651526 |
2014 |
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The presence of IBD, but not the genetic risk load, was correlated to differential mRNA expression for IL6 in unstimulated peripheral blood mononuclear cells and to IL23A and RORC in response to stimulation.
|
24662057 |
2014 |
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, IL-6 and TGFβ1 were overexpressed (RQ>10) in non-inflamed mucosa from IBD patients compared to the normal mucosa from the controls.
|
28088612 |
2017 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
T helper 17 (Th17)-cell differentiation triggered by interleukin-6 (IL-6) via STAT3 activation promotes inflammation in inflammatory bowel disease (IBD) patients.
|
30770344 |
2019 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Canonical NF-κB pathway activation is well studied in IBD and is associated with the rapid, acute production of diverse proinflammatory mediators, such as COX-2, IL-1β, and IL-6.
|
27508514 |
2016 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Both PDGF-BB and interleukin 6 (IL-6) showed the strongest correlations with clinical features of IBD.
|
31567972 |
2019 |
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The present study provides a quantitative analysis regarding the Th17/Treg cell balance in peripheral blood of children with IBD and its association with serum IL-6 and IL-23 level.
|
29441874 |
2017 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
These results confirmed that the Th17 cell subset was specifically activated in PP and demonstrated that IL‑6 is required in Th17 cell activation, which are important to the clinical treatment of IBD.
|
24430732 |
2014 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Gastrointestinal perforation may be a specific concern for agents directed at interleukin-6 pathways, and some reports have raised the question of whether interleukin-17 inhibition may elevate inflammatory bowel disease risk.
|
29149926 |
2018 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Cytokine expression in intestinal mucosal biopsies. In situ hybridisation of the mRNA for interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha in inflammatory bowel disease.
|
7841354 |
1995 |
Inflammatory Bowel Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Meta-analyses showed that polymorphisms in TLR2 (rs3804099, OR (95% CI) = 2.17 (1.35-3.47)], rs11938228 [OR = 0.64 (0.43-0.96)], TLR4 (rs5030728) [OR = 3.18 (1.63-6.21)], TLR9 (rs352139) [OR = 0.43 (0.21-0.88)], TNFRSF1A (rs4149570) [OR = 2.06 (1.02-4.17)], IFNG (rs2430561) [OR = 1.66 (1.05-2.63)], IL6 (rs10499563) [OR = 1.65 (1.04-2.63)] and IL1B (rs4848306) [OR = 1.88 (1.05-3.35)] were significantly associated with response among IBD patients using clinical response criteria.
|
27417569 |
2016 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Comparing the change of the variables indicated a significant decrease in fecal calprotectin (P < 0.001), Mayo score (P < 0.001), ESR (P < 0.001), INF-γ (P < 0.001), IL-6 (P < 0.001), waist circumference (P = 0.02), Diastolic Blood Pressure (DBP) (P < 0.001), and Systolic Blood Pressure (SBP) (P < 0.001) and a significant increase in TGF-β (P < 0.001) and Inflammatory Bowel Disease Questionnaire-Short form (IBDQ-9) score (P < 0.001) in the GF and FO groups compared to the control.
|
31519285 |
2019 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Targeting IL-6 may reduce neutrophil-associated extraintestinal manifestations in IBD patients.
|
29684360 |
2018 |
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Furthermore, IRF4 levels significantly correlated with IL-6 and IL-17 mRNA expression and to a lesser extent with IL-22 mRNA expression in IBD.
|
21305677 |
2011 |
Inflammatory Bowel Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This study aimed to assess the frequency of genotypes and haplotypes of the G/C polymorphism of IL-6 in IBD patients.
|
11713964 |
2001 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data define a new function of IL-6 and suggest that caution should be exercised when targeting IL-6 in IBD patients, particularly those with defects in IL-10 signaling.
|
31679013 |
2019 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, our data identify IRF4 as a key regulator of mucosal IL-6 production in T cell-dependent experimental colitis and suggest that IRF4 might provide a therapeutic target for IBDs.
|
18535667 |
2008 |
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Increased IL-6 expression has been reported in IBD patients, which may be associated with intestinal barrier function through discontinuous tight junction (TJ).
|
27980357 |
2016 |
Inflammatory Bowel Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of the study was to describe the levels of circulating monocyte/macrophage pro-inflammatory cytokines (TNF-alpha, IL-1beta IL-6, and IL-8) and an anti-inflammatory cytokine (IL-10) in inflammatory bowel disease (IBD) and colorectal cancer (CRC) patients and healthy controls.
|
19578817 |
2009 |
Inflammatory Bowel Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study using reverse transcriptase polymerase chain reaction (RT-PCR) we isolated and characterised a truncated form of amplified cDNA reverse-transcribed from IL-6 receptor mRNA both from human hepatoma cell line HepG2 and mononuclear cells from inflammatory bowel disease (IBD) patients.
|
10397166 |
1999 |